Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 ...

Exogenous attention is a rapid, involuntary mechanism that automatically reallocates processing resources toward salient stimuli. It enhances visual sensitivity in the vicinity of the salient stimulus ...

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects ...

GLP-1 receptor agonists (GLP-1 RAs) are transforming metabolic disease treatment, with analytical chemists playing a critical role in formulation, stability testing, and clinical trial support for ...

Sacituzumab govitecan maintained physical functioning scores, contrasting with chemotherapy's deterioration in advanced TNBC patients. Time to deterioration in fatigue was comparable between ...

This important study shows that different forms and mixtures of cardenolide toxins in tropical milkweed, especially nitrogen- and sulfur-containing types, change how monarch caterpillars eat, grow, ...

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...

Researchers developed a blood test that spots ALS with 90% accuracy. The 46-gene panel could cut diagnostic delays that now ...

Barclays 23rd Annual Global Technology Conference December 11, 2025 11:05 AM ESTCompany ParticipantsJudson Althoff - ...

As buildings face tougher climate demands, green certifications are shifting from checklists to real performance. Here's how ...

T-DXd plus pertuzumab improved quality-of-life outcomes, with fewer skin and mucosal symptoms but more gastrointestinal issues compared to the standard regimen. Both treatment arms showed similar pain ...

Healthcare providers shortened buying cycles from eight months to under seven as financial pressures force CFOs to demand proven returns over experimental pilots [1]. Half of all practices now deploy ...